New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma

Share Article

New genome sequencing work by scientists in Canada and the U.S. is paving the way for a more personalized approach to mesothelioma therapy.

Genomics May Be Key to Mesothelioma Cure

Genomic Work May Improve Mesothelioma Treatment

...a unique opportunity to learn how to best analyze, interpret and apply rapidly emerging molecular information in the clinic.

Genomic medicine experts have sequenced the genomes of two people with peritoneal mesothelioma, revealing, for the first time, key information for understanding and treating this intractable cancer. Click here to read the newly posted story on the Surviving Mesothelioma website.

Research scientists at the University of British Columbia, the British Columbia Cancer Agency, and PhenoPath lab in Seattle, Washington used genome mapping to reveal underlying molecular alterations and mutations that can lead to peritoneal mesothelioma.

“The Personalized OncoGenomics initiative at the British Columbia Cancer Agency provides a unique opportunity to learn how to best analyze, interpret and apply rapidly emerging molecular information in the clinic,” writes lead investigator Brandon Sheffield of the University of British Columbia.

News of the mesothelioma genome sequencing, published in the online open access medical journal PLoS One, may eventually help clinicians treat the disease more effectively.

“Understanding the genetic anomalies and mutations that underlie a rare cancer like peritoneal mesothelioma is vital to treating it effectively and even to eventually finding a cure,” says Surviving Mesothelioma’s Managing Editor, Alex Strauss.

To read the full article on the genome sequencing of peritoneal mesothelioma and what it may mean for future treatments, see Peritoneal Mesothelioma: Genome Sequencing Paves the Way for Personalized Treatments now available on the Surviving Mesothelioma website.

Sheffield, BS, “Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing”, March 23, 2015, PLoS One, http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119689

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website